Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
Eloísa RivaPatricio José DuarteBryan ValcarcelGuillermina RemaggiIvan MurrietaAriel CorzoDaniel Del CarpioCamila PeñaJule VasquezVirginia BoveLarissa TeixeiraGuilherme Fleury-PeriniSebastian YantornoCésar SamánezSergio LoprestiMilagros AltamiranoLuis VillelaGuillermo J Ruiz-ArguellesGuillermo J Ruiz-DelgadoEfreen MontañoVerónica VerriElia Zamora PérezFernando Pérez-JacoboHenry IdroboHumberto Martínez-CorderoBrady Ernesto Beltrán-GárateJhoanna RamírezJorge J CastilloLuis E Malpica-CastilloPublished in: JCO global oncology (2022)
In Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the IPSSWM score as a prognostic factor for OS and PFS. There is an unmet need to improve access to recommended diagnostic approaches and therapies in Latin America.